27 citations
,
January 2018 in “Drug Delivery” In this study, researchers investigated a new local drug delivery system using glycol chitosan hydrogel and doxorubicin (GC10/DOX) for thyroid cancer in mice, finding it produced a stronger antitumor effect compared to conventional treatment methods.
1 citations
,
July 2014 in “International Journal of Dermatology” A cancer patient developed a type of hair loss after starting a cancer drug called vandetanib.
2 citations
,
July 2023 in “International Journal of Clinical and Experimental Medicine Research” This study found that for thyroid cancer patients who underwent radical mastectomy, the combination of CAF regimen and fufangbanmao capsule improved short-term clinical efficacy, enhanced immune function, reduced drug toxicity, and positively impacted quality of life compared to the CAF regimen alone.
8 citations
,
August 2020 in “PLOS Computational Biology” This study presents a computational approach, CATNIP, which repurposes drugs using only their biological and chemical information, predicting new uses like adrenergic uptake inhibitors for Parkinson's and vandetanib for Type 2 Diabetes.
39 citations
,
June 2019 in “Frontiers in Endocrinology” This study reported that while both sorafenib and lenvatinib may require dose modifications due to adverse events in treating advanced or metastatic thyroid cancers, key differences in side effect profiles were observed.